This study analyses the growth and the growth hormone secretion of children given various conditioning protocols before bone marrow transplantation (BMT). Twenty nine children (14 boys, 15 girls) given BMT were classified according to their conditioning protocol: total body irradiation (TBI) given as a single exposure of 10 Grays (Gy, group I, 11 cases), or 8 Gy (group II, four cases), 12 Gy given as six fractionated doses (Group HI, seven cases), or chemotherapy alone (group IV, seven cases). The arginine-insulin stimulated growth hormone peak, 2-7.5 years after BMT, was >10 WAg/l in all patients except four from group I (6.9-8.9 pg/l). A second growth hormone secretion evaluation was performed in 10 group I patients because of persistent low growth velocity despite a normal growth hormone peak. There were no significant changes in the mean (SEM) stimulated growth hormone peak (18-4 (2.2) v 20*1 (3.6) ig/l) at 3 (0.3) to 5-2 (0.6) years after BMT. The sleep growth hormone peaks and concentrations (n=6) were normal. The mean cumulative height changes (SD) during the three years after BMT were: -1-4 (0.2) in group I, -0.1 (0-4) in group l, -0.4 (0.2) in group HI, and 1 5 (0.5) in group IV; this was significant in groups I and IV. The final heights of two monozygotic twins (BMT donor and recipient) had differed by 17-5 cm, despite them both having normal growth hormone peaks and puberty. Eight patients, treated for congenital immune deficiency syndrome, were growth retarded at the time of BMT. Of these, only those conditioned by chemotherapy alone had significant catch up growth (2 (0.6) SD) while those conditioned by a single 8 Gy exposure did not (0(0-4) SD).
Abstract
This study analyses the growth and the growth hormone secretion of children given various conditioning protocols before bone marrow transplantation (BMT). Twenty nine children (14 boys, 15 girls) given BMT were classified according to their conditioning protocol: total body irradiation (TBI) given as a single exposure of 10 Grays (Gy, group I, 11 cases), or 8 Gy (group II, four cases), 12 Gy given as six fractionated doses (Group HI, seven cases), or chemotherapy alone (group IV, seven cases). The arginine-insulin stimulated growth hormone peak, 2-7.5 years after BMT, was >10 WAg/l in all patients except four from group I (6.9-8.9 pg/l). A second growth hormone secretion evaluation was performed in 10 group I patients because of persistent low growth velocity despite a normal growth hormone peak. There were no significant changes in the mean (SEM) stimulated growth hormone peak (2. 2) v 20*1 (3.6) ig/l) at 3 (0.3) to 5-2 (0.6) years after BMT. The sleep growth hormone peaks and concentrations (n=6) were normal. The mean cumulative height changes (SD) during the three years after BMT were: -1-4 (0.2) in group I, -0.1 (0-4) in group l, -0.4 (0.2) in group HI, and 1 5 (0.5) in group IV; this was significant in groups I and IV. The final heights of two monozygotic twins (BMT donor and recipient) had differed by cm, despite them both having normal growth hormone peaks and puberty. Eight patients, treated for congenital immune deficiency syndrome, were growth retarded at the time of BMT. Of these, only those conditioned by chemotherapy alone had significant catch up growth (2 (0.6) SD) while those conditioned by a single 8 Gy exposure did not (0(0-4) SD).
It is concluded that the total radiation dose is critical for growth evolution, as is the fractionation schedule. For the TBI doses and the interval since BMT studied, there was no correlation between growth hormone peak and the height loss. The rapidity of decreased growth velocity after TBI and the comparison between the monozygotic twins suggest that radiation induced skeletal lesions are partly responsible for the decreased growth. ( This study evaluates the growth and growth hormone secretion of patients given various conditioning protocols before BMT. These children were divided into three groups according to their radiation doses and compared with a group of patients who had been conditioned for BMT by intensive chemotherapy alone.
Patients and methods

PATIENTS
Twenty nine children (14 included.
The 29 patients were followed up from the time of BMT. Height, weight, and genital maturation, basal plasma thyroid stimulating hormone and free thyroxine were recorded each year. The duration of this clinical follow up varied from three to 10 years. All patients but two (cases 7 and 11) were prepubertal throughout this follow up period. The first growth hormone evaluations, using arginine-insulin stimulation and plasma insulin-like growth factor-I (IGF-I) evaluation, were performed at least two years after transplantation (range 2-6-6 years, mean 3-1 (0-2) years). This interval was not significantly different from one group to another. A second growth hormone evaluation using arginine-insuln stimulation was performed in 10 patients. Five of these patients were also evaluated for their growth hormone secretion during sleep the night before the stimulation test. This second growth hormone evaluation was performed in all patients who continued to show a decreased growth velocity, in spite of a normal growth hormone peak response to the first stimulation and normal basal plasma thyroid stimulating hormone and thyroxine. In this 
group (n= 10), the interval between the BMT and the first growth hormone evaluation was 3 (0-3) years and 5-2 (0-6) 20-1 (3) (4) (5) (6) stimulation (Rg/l) were 16-1 (2) (3) (4) (5) (3) (4) (5) (6) in group IV. Only the group I patients (TBI, 10 Gyx 1) had a significantly lower growth hormone peak value than that of group IV patients (chemotherapy alone, p<0-02). Three patients from group I had growth hormone peak values ([tg/l) below 10:7-5 (case 1), 6-9 (case 10), and 8-9 (case 11). The concomitant growth hormone peak and concentration during sleep of case 1 were normal (11-6 and 3-6 [tg/l respectively). The plasma IGF-1 values were interpreted according to the sex and age of patients.9 Eleven of the 29 patients had plasma IGF-1 values below the lower limits of normal. These low values ofplasma IGF-I were found in the two patients who were low growth hormone responders (cases 1 and 10) and in nine normal growth hormone responders (cases 3, 5, 12, 16, 18, 22, 24, 27, and 28). All had normal plasma thyroxine values. Plasma IGF-I values were not correlated with the body mass index (height/weight2). The mean values of this parameter in the whole population and in group I were normal (46 (5) centile).
At the second growth hormone evaluation (table 2), performed 2-2 years after the first evaluation, the mean growth hormone peak after arginine-insulin stimulation had not changed significantly (18-4 (2-2) v 20-1 (3) (4) (5) (6) [ig/l, n= 10).
This evaluation confirmed the low growth hormone peak in case 11 and showed a lower growth hormone peak in case 3. Five patients with normal stimulated growth hormone peaks had normal growth hormone peaks and concentrations during sleep. The mean plasma IGF-I value did not change significantly (0 7 (0-1) v 0-9 (0-1) U/ml). Three of the four patients having low IGF-I values at the first evaluation had normal value at the second.
OTHER ENDOCRINE DATA Plasma free thyroxine was low in three patients (cases 2, 6, and 19). The basal plasma thyroid stimulating hormone values were raised (>5 mU/l) in seven patients (cases 1, 2, 4-6, 10, 17). Six of them belonged to group I and one to group III. These patients were therefore given L-thyroxine replacement treatment (50-100 tg/ m2/day) from that time. This treatment did not improve their growth rate. Basal and insulin stimulated plasma cortisol concentrations were normal in all cases (data not shown). Only two boys were pubertal (cases 7 and 11) with plasma testosterone values of 2-9 and 9 7 nmol/l respectively. them were treated with human growth hormone. The growth velocity was normalised in one and increased for age in a second (fig 2) . The extent of growth retardation after a single 10 Gy exposure despite normal growth hormone secretion was documented by comparing the growth evolution of monozygotic twins: the case 7 boy had a final height 17-5 cm below that of his brother who donated the bone marrow for transplantation. This occurred in spite of case 7 having a normal growth hormone peak, plasma IGF-I concentration, and a similar age at pubertal development (fig 3) . Growth was further analysed in the eight patients treated for congenital immune deficiency syndrome who were growth retarded at the time of BMT. The height changes after three years of those given TBI (8 Gy single exposure, cases [12] [13] [14] [15] were compared with those of the patients given chemotherapy alone (cases 23-26) (fig 2) . The TBI group had no change in mean height (0 (0-4) SD) but the chemotherapy group had a mean height gain of 2 (0-6) SD indicating strong catch up growth. The difference between these two groups was significant (p<0-01). Data of upper segment length, measured as the sitting height, were collected at the first evaluation (3-8 (0-7) years after BMT) in 14 patients. When expressed as the SD score, it was found to be a mean (SD) -1-8 (0-4) while the concomitant height was -1-7 (0-4). given cranial irradiation were not included in this study. Second, is the growth related to the conditioning protocol? Only the group of children who had been exposed to a single exposure of 10 Gy failed to grow, while patients given single dose of 8 Gy or a fractionated dose of 12 Gy grew normally and those conditioned by chemotherapy had catch up growth.
Growth hormone deficiency induced by TBI is one of the potential causes ofgrowth retardation. Its frequency is difficult to evaluate as the published studies were performed after various protocols of TBI, times after TBI, and methods of growth hormone stimulation. The growth hormone peak ([tgI1) 6 Neuhauser et al described roentgenograph vertebral body changes after spinal irradiation.'7 They showed the importance of the total radiation dose, duration of treatment, and age at irradiation. Doses of 10 Gy delivered in one week produced changes in children younger than 2 years. '7 Tefft showed that these changes occurred after lower doses when delivered to children less than 1 year old. 8 Willi et al found a persistant decreased growth velocity in patients who had transplants for neuroblastoma. '9 The role of chemotherapy, especially melphalan, was discussed. However, their patients also received local radiotherapy, which may decrease growth velocity. Papadimitriou et al have found that sitting height SD scores had been affected more than subischial leg length in 13 children evaluated after a mean interval time of 3-2 years." In the present study, sitting height and total height, evaluated 3-8 years after BMT, were similar.
In conclusion, the decrease in growth velocity occurred only in patients conditioned for transplantation by 10 Gy delivered in a single exposure. The mechanism of this decrease is unknown. Four patients had growth hormone peaks in the lower range. The normalisation of their growth velocity on standard doses of human growth hormone treatment favours the role of this growth hormone decrease in the decreased growth. However, the absence of agreement between growth hormone peak, plasma IGF-I concentrations, and growth in this group indicates that the contribution of growth hormone deficiency to the decreased growth is not clear. Other mechanisms for growth retardation were ruled out. As other studies showed that single dose induced complications more frequently than fractionated doses, our data are a further argument favouring conditioning by fractionated schedule or chemotherapy.
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